Annovis Secures FDA Agreement on Integrated Summary of Safety Plan, Combining Alzheimer’s and Parkinson’s Data Ahead of Buntanetap NDA
FDA agrees with plan to pool safety data from four Alzheimer’s and Parkinson’s studies and to integrate it at the
FDA agrees with plan to pool safety data from four Alzheimer’s and Parkinson’s studies and to integrate it at the
MALVERN, Pa., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3
Last patient, last visit of the 6-month treatment period in the Phase 3 DUET-AD study is scheduled for December 31,
U.S. Patent No. 12,780,831 covers posiphen (buntanetap) D-tartrate Form B, a highly crystalline dihydrate, together
Annovis Chairman of the Board invested $5.0 million as part of the underwritten public offering Company expects cash
MALVERN, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3
MALVERN, Pa., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3
MALVERN, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase
Pivotal Phase 3 Alzheimer’s disease (AD) trial is fully enrolled with a total number of 850 patients, exceeding